The market expects GSK (GSK) to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended September 2024. This widely-known consensus outlook is ...
GSK has agreed to pay up to $2.2 billion to settle most lawsuits in US state courts claiming that a discontinued version of ...
GSK is pumping £50 million (about $65 million) into a five-year collaboration with the University of Cambridge and Cambridge ...
The Wall Street Journal on MSN13d
GSK to Pay Over $2 Billion in Bid to End Most U.S. Zantac LawsuitsGSK GSK1.11%increase; green up pointing triangle agreed to pay more than $2 billion to settle almost all remaining liability ...
British drugmaker GlaxoSmithKline sued Moderna in U.S. federal court in Delaware on Tuesday, accusing its American rival of ...
GSK shares jumped as much as 6.5% on Thursday after the British drugmaker struck a $2.2 billion settlement over U.S. lawsuits ...
Check the time stamp on this data. Updated AI-Generated Signals for Gsk Plc American Depositary Shares (each Representing Two ...
GSK PLC GSK shares inched up 0.03% to £14.97 Thursday, on what proved to be an all-around favorable trading session for the ...
GlobalData on MSN1d
Cambridge University and GSK sign immunology R&D collaborationGSK has announced a £50m ($54.3m) investment in a new partnership with the University of Cambridge and Cambridge University ...
Wave Life Sciences has taken a step toward validating a new modality, becoming the first group to report therapeutic RNA ...
GSK has settled lawsuits in the US that alleged the drugmaker’s now-discontinued heartburn drug Zantac triggered cancer ...
GSK Plc’s experimental drug to treat a common inflammatory nasal condition showed positive results in two late-stage trials ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback